Skip to main content
S&P 5007,765.36-0.47%DOW51,231.64+0.10%NASDAQ27,193.34-1.25%BTC$83,260.00+1.11%ETH$2,505.59-1.13%GOLD$4,208.70+1.24%OIL$90.53-1.05%
Smart Investors Daily
SID Premium
AD

OTC · ADIA

Adia Nutrition, Inc.

Financial Services · Shell Companies

$0.15

Up+$0.00 (+0.00%)

Updated Oct 9, 2026, 12:16 PM

SID Score

4.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
19.82M
P/E ratio
-26,250
Dividend yield
0.00%
52-week range
$0.02 – $0.28
Volume
41.54K
Avg. volume
57.23K

Price performance · ADIA

ADIA price history

1M range · 0 trading sessions · Daily adjusted prices

ADIA does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest ADIA news

The latest Smart Investors Daily articles mentioning ADIA.

Stock researchCompany · Overview

ADIA research

Overview

Company profile and research snapshot.

Company profile

ADIA NUTRITION INC

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 29, 2026

Adia Med Inc. Announces Adia Labs Expansion of Regenerative Product Line

New research-use products - Adia30M, AdiaClear, and AdiaEXO - give physicians more options in cell count, format, and concentration for investigational studies.Winter Park, Florida--(Newsfile Corp. - September 29, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies, biologics, and physician-supervised investigational research, today announced that its laboratory subsidiary, Adia Labs LLC, has expanded its product portfolio with three new...

Yahoo · Sep 22, 2026

Adia Med Inc. Announces Adia Labs Biologic Inventory Now Exceeds $1.5 Million to Meet Rising Demand for the Company's Biological Products

Winter Park, Florida--(Newsfile Corp. - September 22, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies, biologics, and physician-supervised investigational research, today announced that the estimated retail value of biologic inventory at its laboratory division, Adia Labs LLC, now exceeds $1.5 million, driven by accelerating demand for the Company's biologic products as its ongoing clinical studies expand.Management estimates that Adia Labs'...

Yahoo · Sep 15, 2026

Adia Med Submits Fifth 2026 Clinical Study to IRB: Osteoarthritis Protocol for One-Time Systemic Treatment

Winter Park, Florida--(Newsfile Corp. - September 15, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company, today announced that its subsidiary, Adia Med of Winter Park, LLC, has submitted a clinical study protocol to an Institutional Review Board for review and approval.The proposed study is designed to evaluate a one-time systemic treatment with AdiaVita, the Company's umbilical cord blood-derived stem cell and exosome product, in adults with osteoarthritis. Participation is...

Yahoo · Sep 8, 2026

Nasdaq Shareholder Requirements Just Verified By Adia Med

Winter Park, Florida--(Newsfile Corp. - September 8, 2026) - Nasdaq requires companies seeking an initial listing on the Nasdaq Capital Market to have a sufficiently broad public shareholder base. That distribution test includes:At least 300 round-lot holders;A round-lot holder generally meaning a shareholder holding at least 100 unrestricted shares; andAdia Med has just verified that it currently has 361 round-lot holders, or 61 holders above Nasdaq's 300-holder minimum.Nasdaq Shareholder...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By